Introducing a New Barbie with Type 1 Diabetes
Mattel has unveiled a groundbreaking Barbie doll that represents children with type 1 diabetes. This new doll features Barbie’s classic pink design, now equipped with a continuous glucose monitor and an insulin pump.
“The introduction of Barbie dolls with type 1 diabetes is a vital part of our dedication to inclusivity,” stated Christa Burger, the senior vice president of Barbie at Mattel. “Barbie plays a significant role in shaping how children view the world. By showcasing medical conditions like T1D, we’re helping more kids see themselves in the dolls they cherish.”
This doll is part of Mattel’s broader Fashionista line, which aims to reflect diverse experiences and encourage various perspectives.
In collaboration with Breakthrough T1D, a top organization for type 1 diabetes research and advocacy, Mattel ensured that the doll accurately represents the community. The doll’s continuous glucose monitor is secured with heart-shaped medical tape, and it includes a Barbie phone for tracking blood sugar through a connected app. This device mimics real-life monitors, continuously monitoring glucose levels.
The doll also has an insulin pump attached at her lower back for automatic insulin delivery as needed.
The design of her outfit—a blue polka dot top and matching skirt—was inspired by the symbols commonly associated with diabetes awareness.
Additionally, this Barbie comes with a wallet for carrying essential diabetes supplies and snacks.
“This initiative enhances the visibility of conditions impacting many families,” commented Dr. Aaron J. Kowalski, CEO of Breakthrough T1D. “We’re proud to partner with a brand that emphasizes that living with Type 1 diabetes can be vibrant and empowering.”
To celebrate the launch, Barbie also recognized two advocates in the field of type 1 diabetes: Robin Arzon, a US Peloton instructor, and UK model Liramos, who received their own unique Barbie dolls.
Type 1 diabetes is a chronic autoimmune condition that results in little or no insulin production by the pancreas, making insulin therapy essential for those affected. Currently, around 1.24 million people live with type 1 diabetes in the U.S., a figure projected to rise to 5 million by 2050.





